IONSIonis Pharmaceuticals, Inc.

$13B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$225M+19.6% YoY

Gross Profit

$221M98.2% margin

Operating Income

-$66M-29.3% margin

Net Income

-$66M-29.4% margin

EPS (Diluted)

$-0.45

QoQ Revenue Growth

+88.5%

Cash Flow

Operating Cash Flow

-$120M

Free Cash Flow

-$140M

Stock-Based Comp.

$31M

Balance Sheet

Total Assets

$2.7B

Total Liabilities

$2.4B

Stockholders' Equity

$264M

Cash & Equivalents

$294M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$225M	$188M	+19.6%
Gross Profit	$221M	$186M	+18.9%
Operating Income	-$66M	-$90M	+26.7%
Net Income	-$66M	-$85M	+22.3%

Revenue Segments

Research and Development Revenue

$153M34%

Collaborative Agreement Revenue

$142M32%

Commercial

$72M16%

SPINRAZA Royalties

$57M13%

Other Commercial

$12M3%

Product

$8M2%

Licensing and Other Royalties

$3M1%

IONS Q2 2024 Earnings — Ionis Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena